|Drugs of the Future|
| || |
|Drugs Fut 2007, 32(4): 315|
Copyright 2007 Clarivate Analytics
Revill, P., Mealy, N., Serradell, N., Bolos, J., Rosa, E.
|Panobinostat (LBH-589) is a member of the hydroxamic acid group of histone deacetylase (HDAC) inhibitors that have been shown to impede multiple pathways implicated in cancer and reverse epigenetic events associated with cancer, thereby reducing survival and inducing apoptosis in cancer cells. Panobinostat is being investigated in various hematological malignancies, including chronic myelogenous leukemia (CML) and multiple myeloma, and in solid tumors. Preclinical data indicate efficacy against drug-resistant cancer cells, both as a single agent and in combination with other therapies. A phase I clinical study has demonstrated activity in treatment-experienced patients with cutaneous T-cell lymphoma (CTCL) and phase II/III trials for this condition and other hematological malignancies are ongoing.|
Full Text: HTML, PDF
| || |